Vandria SA

Vandria's VNA-318 Shows Promising Phase 1 Results with Novel Dual-Action Mechanism for Alzheimer's Disease

- Vandria's VNA-318, a first-in-class oral brain-penetrant small molecule, demonstrated excellent safety and tolerability in a Phase 1 trial involving 92 healthy male subjects with no severe adverse events. - Single doses of VNA-318 produced statistically significant (p<0.001) and dose-dependent changes in key plasma target engagement biomarkers, supporting its novel dual mechanism targeting inflammation reduction and mitochondrial function improvement. - The compound showed predictable pharmacokinetics with a long half-life supporting once-daily dosing and confirmed brain penetration in humans, validating preclinical findings. - Vandria plans to advance VNA-318 to Phase 2 proof-of-concept trials for Alzheimer's disease and explore applications in other CNS disorders including mild cognitive impairment and major depressive disorder.